Atai Life Sciences N.V. - Special Call Transcript
Good morning, everybody, and welcome to Atai's webinar focused on the Cognitive Impairment Associated with Schizophrenia. I'd like to thank everybody for joining both our speakers, Matt and Rich as well as the audience members. The goals of today's call or webinar are really twofold.
The first is to provide some -- to provide a little more clarity, a little bit more color on the results that we announced last year -- late last year on RL-007 and the initial proof of mechanism trial of this compound in schizophrenia and cognitive impairment associated with schizophrenia in particular. We talked a little bit about the EEG results that we found there as well as some of the symptomatic benefits that we're seeing. We, again, want to give you a little bit more color there and also provide a touch upon some of the ERP results that were down there.
What's equally important, however, is that we want to provide some context for these results and really give the audience a little bit more information on the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
